Evidence map›Paper›PMID 41152941›Full record

ArticleJournal of neuroinflammation2025

Transcriptional and neuroprotective effects of hexokinase-2 inhibitors administered after stroke.

Seok Joon Won, Gӧkhan Uruk, Nguyen Mai, Chia-Ling Tu, Devran Ogut, Sona Asatryan, Ebony Mocanu, Rachel Shon, Kyungsoo Kim, Khukheper Awakoaiye and 4 more

Abstract read
In one paragraph

Article in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Seok Joon WonDepartment of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA, 94121, USA.
Gӧkhan UrukDepartment of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA, 94121, USA.
Nguyen MaiDepartment of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA, 94121, USA.
Chia-Ling TuDepartment of Medicine, University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA, 94158, USA.
Devran OgutDepartment of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA, 94121, USA.
Sona AsatryanDepartment of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA, 94121, USA.
Ebony MocanuDepartment of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA, 94121, USA.
Rachel ShonDepartment of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA, 94121, USA.
Kyungsoo KimDepartment of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA, 94121, USA.
Khukheper AwakoaiyeDepartment of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA, 94121, USA.
Kajsa ArkeliusDepartment of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA, 94121, USA.
Wenhan ChangDepartment of Medicine, University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA, 94158, USA.
Neel S SinghalDepartment of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA, 94121, USA. Neel.singhal@ucsf.edu.
Raymond A SwansonDepartment of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA, 94121, USA. Raymond.swanson@ucsf.edu.

Funding

Skeletal Biology and Biomechanics (SBB) CoreP30AR075055 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Wenhan Chang · 2019 to 2026
$7.1M
UCSF Core Center for Musculoskeletal Biology and MedicineP30AR066262 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MAJUMDAR, SHARMILA · 2014 to 2018
$3.0M
NINDS Research Education Programs for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25)UE5NS070680 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Scott Andrew Josephson · 2024 to 2026
$2.6M
Vitamin D and beta-amyloid signaling in hyperparathyroidismRF1AG075742 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHANG, WENHAN, KOH, JAMES · 2023 to 2025
$2.4M
BLRD VA I01 BX005851BLRD VA I01 BX006251BLRD VA IK2 BX005369BLRD VA IK6 BX004835NIAMS NIH HHS P30 AR066262NIAMS NIH HHS P30 AR075055NIA NIH HHS RF1 AG075742NIH HHS 5UE5NS070680NINDS NIH HHS UE5 NS070680U.S. Department of Veterans Affairs 1IK2BX005369U.S. Department of Veterans Affairs 1IK6BX004835U.S. Department of Veterans Affairs BX006251U.S. National Institutes of Health P30AR075055
6 · The paper itself

Abstract

backgroundThe delayed inflammatory response induced by stroke can cause secondary injury to peri-infarct tissue. Microglia and other immune cells that mediate this injury require increased glycolytic flux for pro-inflammatory activation. These cells, unlike neurons, astrocytes, and most other cell types, utilize hexokinase-2 (HK2) rather than hexokinase-1 for glycolysis. Accordingly, HK2 inhibitors may selectively target immune cells to suppress post-stroke inflammation. Here we compared the effects of the non-selective hexokinase inhibitor 2-deoxyglucose to the HK2-selective inhibitors lonidamine and 3-bromopyruvate on gene expression changes and secondary injury after stroke.

methodsStroke was induced in mouse motor cortex by photothrombosis, and the hexokinase inhibitors were administered intraperitoneally beginning three hours after stroke. Gene expression in microglia and neurons was evaluated in the adjacent and more distant peri-infarct cortex using in situ spatially defined cell type-specific whole transcriptomic profiling. Tissue injury was quantified using immunohistochemical methods, and mouse functional impairment was assessed over two weeks after stroke by the cylinder, rotating beam, and skilled reaching tasks.

resultsPeri-infarct microglia exhibited an upregulation in pro-inflammatory gene expression, while neighboring neurons showed an upregulation in cell stress/death pathways. These changes were spatially dependent, being greatest adjacent to the infarct edge. The microglial gene expression changes correlated with both morphological activation and increased CD11b expression. The three hexokinase inhibitors had similar effects on gene expression, consistent with a shared mechanism of action. They suppressed pro-inflammatory gene upregulation in peri-infarct microglia, attenuated the cell stress responses in neighboring neurons, and had minimal effect on gene expression in uninjured cortex, with the HK2-selective inhibitors having greater anti-inflammatory effects than 2-deoxyglucose. The HK2-selective inhibitors were also more effective in suppressing microglial morphology changes and CD11b expression, and in suppressing oxidative stress and neurite loss in peri-infarct neurons. Mice treated with the HK2 inhibitor 3-bromopyruvate for four days after stroke showed long-term improvement in functional outcomes.

conclusionsThese findings confirm an essential role for glycolysis in post-stroke, pro-inflammatory microglial activation. Selective HK2 inhibitors provide a clinically applicable approach for suppressing microglial activation and thereby improving outcomes after stroke.

Indexed as

Enzyme InhibitorsHexokinaseNeuroprotective AgentsStrokeAnimalsDeoxyglucoseMaleMiceMice, Inbred C57BLMicrogliaPyruvatesbromopyruvateDeoxyglucoseEnzyme InhibitorsHexokinasehexokinase 2, mouseNeuroprotective AgentsPyruvatesBrainHexokinaseIschemiaMicrogliaSpatial transcriptomics

Identifiers

PMID41152941
PMCPMC12570821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.